Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Numen logo — Engineering a future without cancer deaths.

Numen

Engineering a future without cancer deaths.

Founded 2021 United States San Francisco, United States 18 employees Pre-Seed Total: $5.00M Health Care

General Information

Company Name Numen
Founded Year 2021
Location United States San Francisco, United States
Employees 18
Industries Health Care
Funding Stage Pre-Seed
Business Model B2C, D2C, B2B
Revenue Model Product Sales, Service Fee, Subscription
Social

BounceWatch is an independent company data service, not affiliated with Numen. To contact Numen, visit numen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Numen compare?

A PDF of Numen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Numen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Numen

Numen specializes in developing advanced health care solutions with a focus on synthetic biology and cancer screening. Based in San Francisco, United States, the company caters to healthcare providers, cancer patients, research institutions, and healthcare data analysts.

Founded in 2021, Numen provides services such as rapid at-home diagnostics, health data collection, and proprietary predictive models. It operates on multiple business models, including B2C, D2C, and B2B, generating revenue through product sales, service fees, and subscriptions.

Business keywords: Synthetic Biology, Cancer Screening, At-Home Diagnostics, Lab-Grade Testing, Cancer Biomarkers, Urine Analysis, Rapid Diagnostics, Prostate Cancer Detection, Bladder Cancer Detection, Ovarian Cancer Detection, Biomarker Tracking, Platform Technology, Healthtech Innovation, Personalized Medicine

Services & Products

Rapid at-home diagnostics
Health data collection
Proprietary predictive models

Target Customers

Healthcare providers Cancer patients Research institutions Healthcare data analysts

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round $5.00M 3
Urban Innovation Fund Y Combinator TQ Ventures
Urban Innovation Fund, Y Combinator +1
01 Sep 2023

Numen Alternatives & Competitors

View All Alternatives
Numen vs
Exai Bio
Exai Bio United States

Delivering next-generation liquid biopsy platform for the earliest detection and most accurate cance...

22 employees
Biotechnology, Health Care
Numen vs
Nucleix Ltd.
Nucleix Ltd. Israel

Developing cancer diagnostic panels based on epigenetic bio markers

72 employees
Biotechnology, Health Care
Numen vs
Exosome Diagnostics, a Bio-Techne brand
Exosome Diagnostics, a Bio-Techne brand United States

ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and gu...

Series C
103 employees
Biotechnology, Health Care
View all alternatives

FAQ About Numen

Engineering a future without cancer deaths.
Numen was founded in 2021.
Numen is headquartered in San Francisco, United States.
Numen operates in Health Care. Its work centres on Synthetic Biology, Cancer Screening, At-Home Diagnostics and Lab-Grade Testing. Its customers include Healthcare providers, Cancer patients and Research institutions.
Numen has a B2C, D2C and B2B business model. Its revenue comes from Product Sales, Service Fee and Subscription.
Numen has approximately 18 employees.
Numen has completed 1 funding round, raising a total of $5.00M. The latest funding stage is Pre-Seed.
Numen offers: Rapid at-home diagnostics, Health data collection, Proprietary predictive models.
Top alternatives and competitors to Numen include Exai Bio, Nucleix Ltd., Exosome Diagnostics, a Bio-Techne brand, Beacon Biomedical, Craif Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Numen and Exai Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Numen, https://bouncewatch.com/company/cleancard, updated 29 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout